EV PD‐L2 level, identified for evaluating immunotherapy outcomes, was further validated in an independent cohort including 135 plasma samples from 68 melanoma patients receiving anti‐PD‐1 monotherapy. Here, PDCD1LG2 is linked to melanoma.